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Summary 
Background. One-stop clinics provide comprehensive diagnostic testing in one outpatient 
appointment. They could benefit patients with conditions, such as cancer, whose outcomes are 
improved by early diagnosis, and bring efficiency savings for health systems.  
Objective. To assess the use and outcomes of one-stop clinics for symptoms where cancer is a 
possible diagnosis. 
Design and setting. Systematic review of studies reporting use and outcomes of one-stop clinics in 
primary care patients. 
Method. We searched MEDLINE, Embase, and Cochrane Library for studies assessing one-stop 
clinics for adults referred after presenting to primary care with any symptom that could be indicative of 
cancer. Study selection was carried out independently in duplicate with disagreements resolved 
through discussion. 
Results. Twenty-nine studies were identified, most were conducted in the UK and observational in 
design. Few included a comparison arm. A pooled comparison of the cancer conversion rate of one-
stop and multi-stop clinics was only possible for breast symptoms, and we found no significant 
difference. One-stop clinics were associated with significant reductions in the interval from referral to 
testing (15 versus 75 days) and more patients diagnosed on the same day (79% versus 25%) 
compared to multi-stop pathways. The majority of patients and GPs found one-stop clinics to be 
acceptable. 
Conclusion. This review found one-stop clinics were associated with reduced time from referral to 
testing, increased same day diagnoses, and were acceptable to patients and GPs. Our conclusions 
are limited by high levels of heterogeneity, scarcity of comparator groups, and the overwhelmingly 
observational nature of included studies. 
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Background 
General Practitioners (GPs) see fewer than eight new cases of cancer each year, yet many more 
patients consult their GP with symptoms that could be indicative of cancer.1 In some circumstances, 
GPs may refer patients to ‘one-stop clinics’ to investigate the cause of the symptoms during a single 
outpatient appointment. One-stop clinics are equipped and staffed so that patients may undergo a 
range of tests carried out at the same location, have their results reviewed by specialists, receive a 
diagnosis and, in some cases, have treatment on the same day without referral back to the GP.2 One-
stop clinics are often arranged by symptom and specialty, for example one-stop breast lump clinic or 
urology clinic.  
The rationale behind a one-stop service is that the efficiency of carrying out all tests in a single 
appointment and having the results reviewed immediately by a consultant could speed up the 
diagnostic process, potentially benefitting patients and creating cost savings for the health system.2  
This reasoning appears sound as it has been reported that cancer patients can undergo multiple 
investigations at the request of multiple clinicians before receiving treatment, adding complexity, time, 
and cost to the diagnostic process.3 Furthermore this model of care could have a positive impact on 
patient outcomes as when patients are able to access treatment more quickly their satisfaction with 
the diagnostic process increases and distress is reduced.4,5 Despite this, some authors have 
cautioned that the time saved may not benefit all patients, particularly if further tests or imaging are 
required to confirm a diagnosis.6 
Objectives 
To our knowledge there has been no published systematic review to summarise the evidence for one-
stop clinics for the investigation of symptoms that could be indicative of cancer, and so we set out to 
review the evidence for the use of one-stop clinics. We report the proportion of patients diagnosed 
with cancer or other conditions (the conversion rate) and where possible indications for referral, time 
to testing, appropriateness, other conditions diagnosed, and acceptability to GPs and patients. We 
include direct comparisons with outcomes in patients in the same population referred to multi-stop 
pathways where available.   
  
4 
 
Methods 
Search 
We registered the  systematic review protocol with PROSPERO7 and  searched the following 
electronic databases: MEDLINE, Embase, and the Cochrane Library. The search strategy as reported 
in Supplementary table S1 was adapted for each individual database. Our search strategy was 
purposefully kept broad and included terms describing other diagnostic strategies such as direct 
access and fast track testing. This was done to avoid missing relevant papers because of differences 
in terminology, and with a view to summarising the literature for the other diagnostic strategies which 
has been reported elsewhere.8  
We included studies describing adults (aged ≥18 years) attending primary care and undergoing one-
stop testing for symptoms where cancer diagnosis was a possibility. One-stop clinics were defined as 
clinics accepting referrals from a GP without first consulting a specialist, where all the necessary tests 
for a diagnosis were available on the same day. Some studies included ‘multi-stop’ pathway patients 
as a comparison group. These patients were referred for tests that required multiple clinic 
appointments. Restrictions were not placed on the location of the clinics, nor were clinics excluded if 
their stated aim was something other than cancer detection provided cancer diagnosis was a 
possibility from the symptoms investigated. In addition, reference lists of identified reviews and all 
included studies were checked for studies meeting our inclusion criteria. Finally a ‘related article’ 
search was performed in PubMed on all included studies. No time or language limits were placed on 
the searches.  
Study Selection and Data Extraction 
Retrieved articles were title and abstract screened independently by two reviewers (CFS, AT) and any 
disagreements were resolved through discussion with a third reviewer (BN). The included papers 
were independently read in full by the same two reviewers and disagreements regarding the inclusion 
of papers were resolved through discussion. Four initial screening questions were used for each 
paper, which had to be answered in the affirmative for the paper to be included: 1. One-stop testing 
confirmed? 2. No specialist triage of referrals? 3. GP one-stop referral outcome data reported 
separately? 4. Cancer diagnosis possible? Data from retained studies was extracted by two 
independent reviewers (CFS, GH) into a pre-prepared Excel spreadsheet. The data extraction of the 
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two reviewers was compared, and if necessary, any disagreements were resolved by a third reviewer 
(BN). 
Quality assessment 
The risk of bias and quality of the studies was assessed using the Newcastle-Ottawa tool to review 
cohort studies and a modified version for cross-sectional studies, and the Cochrane Risk of Bias tool 
to assess the risk of bias in randomised controlled trials.9-11 The results of the quality assessment are 
used for descriptive purposes, to provide an overall assessment of the quality of the included studies 
and no studies were excluded based on quality alone. 
Analysis 
We had two primary outcomes of interest. Firstly, the number of cancers diagnosed at a one-stop 
clinic or multi-stop pathway, recorded as an absolute number and expressed as a cancer conversion 
rate (CR). The CR is the number of patients receiving a cancer diagnosis expressed as a proportion 
of all patients attending the clinic. Secondly, the non-cancer diagnoses (with corresponding CR). 
Secondary outcomes of interest were indications for referral, time to diagnosis, the appropriateness of 
referrals, and measures of patient and clinician acceptability.  
CRs were calculated for cancer and non-cancer diagnoses for each study, grouped by 
indication/symptom type, and pooled to give a CR for each indication. Pooled estimates were 
calculated for the CR for each indication; investigated at one-stop clinics or multi-stop pathways 
where appropriate, using the metaprop command in Stata weighted using the Freeman-Tukey double 
arcsine transformation to allow for variation in sample sizes.12,13 A Wilcoxon-Mann-Whitney test was 
used to investigate whether one-stop clinics reduced the interval from referral to testing, from referral 
to diagnosis, and whether more patients referred to one-stop clinics received their diagnosis on the 
same day. In addition, a narrative review of GP and patient acceptability was conducted. 
Results 
The PRISMA flow diagram in Figure 1 outlines the selection of the 29 papers included in the review. 
Table 1 presents a list of the included papers. 
[Figure 1 about here] 
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[Table 1 about here] 
The included papers were published between 1998 and 2016, and all were observational studies with 
the exception of two randomised-controlled trials.14,15 Twenty-five of the studies were carried out in 
clinics based in the UK, two in Australia,16,17 and one each from Ireland18 and Singapore.19 All studies 
were focussed on a specific set of symptoms or specialty i.e. there were no clinics that accepted 
referrals where there was a general suspicion of cancer. The indications for referral included: seven 
studies on post-menopausal or abnormal vaginal bleeding,20-26 six studies on breast symptoms,14,15,27-
30 three for lower gastrointestinal (GI) symptoms,16,31,32 three for elevated prostate specific antigen 
(PSA),17,18,33 three for testicular symptoms,34-36 two for urological symptoms,37,38 two for dyspepsia,39,40 
one for haematuria,19 one for unexplained lymphadenopathy,41 and one for neck lumps.6 When 
reported, one-stop clinics were held in a hospital setting. 
Quality assessment 
The majority of studies (90%) included a representative sample of consecutive patients. The overall 
study quality was poor: most (90%) assessed patient outcomes through retrospective review of 
clinical record data and 90% presented a descriptive analysis only without including a comparator 
group. Only the two randomised controlled trials justified their sample sizes, but neither was blinded. 
One of the randomised controlled trials was judged to be at low risk of bias,14 while the other at 
moderate risk of bias due to missing detail in the paper, suboptimal methods of allocation 
concealment, and attrition of participants with characteristics that may have introduced bias.15 See 
Supplementary tables S2 – S4 for full details. 
Diagnoses by symptom type 
The cancer CR ranged from 1.7% (95% confidence interval (CI) 0.5-3.5%) for lower GI symptoms (3 
studies) to 42.8% (CI 28.5-57.7%) for elevated PSA (3 studies) (Table 2). Only three studies 
presented comparator data from patients referred to multi-stop pathways: one for abnormal vaginal 
bleeding and two for breast symptoms.14,15,24 No significant difference was found in the cancer CR 
between one-stop and multi-stop pathways for breast symptoms (p=0.28) (Table 2).  
Sixty-six percent of the included studies reported non-cancer diagnoses: the non-cancer CR in one-
stop clinics ranged from 30.3% (CI 17.0 – 45.5%) for abnormal vaginal bleeding (5 studies) to 82.1% 
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(CI 61.8 – 95.8%) for lower GI symptoms (3 studies). Two studies reported the number of non-cancer 
diagnoses made in comparator arms: one investigating abnormal vaginal bleeding and the other 
breast symptoms.14,24 In both cases the non-cancer CR was higher in the one-stop clinic, however 
these differences arise from comparing the pooled analysis of one-stop clinics to single studies 
describing the outcomes of a multi-stop comparator clinic and so should be viewed with caution. 
[Table 2 about here] 
For a full breakdown of all cancer and non-cancer diagnoses CRs see Supplementary tables S5 – 
S12. 
Time to testing and diagnosis 
One-stop clinics were associated with a significant reduction in the waiting time between referral and 
clinic appointment from a mean of 75 days (standard deviation (SD) 47 days) in multi-stop pathways 
(4 studies) to 15 days (SD 7 days) in one-stop clinics (9 studies) (r=2.78, p=0.005). Only one study 
reported the change in diagnostic interval and found a significant decrease from usual care clinics (28 
days) associated with the one-stop clinic (15 days, p=0.004).37 Significantly more patients referred to 
one-stop clinics (79.2%) compared to multi-stop clinics (24.7%) were also diagnosed on the same day 
(r=-1.95, p=0.05) (14 studies). 
Appropriateness of referral to one-stop clinic 
Three studies reported the eligibility of patients and the appropriateness of referrals to one-stop 
clinics.14,30,39 Two reported that 3% of the patients referred were excluded because they were deemed 
to be ineligible based on clinician judgement14,39 without giving further detail, and the third reported 
that 34% of patients attending the one-stop breast clinic were referred inappropriately according to UK 
NHS guidelines.30 None of the included studies examined the appropriateness of referrals to one-stop 
clinics relative to usual care clinics. 
Acceptability of one-stop clinics 
Acceptability to patients was assessed in nine studies. Over 87% of patients were either satisfied or 
very satisfied with the service provided by one-stop clinics,22,32,33,41 or felt that it had been a “helpful”40 
experience. In a qualitative evaluation, a one-stop menstrual clinic was rated higher than usual care  
on provision of information, continuity of care, waiting time for an appointment, clinic organisation, 
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explanation of tests, and provision of results.26 Eighty-three percent of patients in another study felt 
that having all of their tests on one day was “of benefit”,39 however this study also reported that fewer 
patients regarded their management in the one-stop dyspepsia clinic as satisfactory compared to 
those seen in the usual care clinic.  
One-stop breast clinics were also found to significantly reduce patient anxiety in the period 
immediately after their appointment, but this disappeared in the longer term.14,15 One study reported 
that women who had received a quicker (one-stop) diagnosis of breast cancer reported higher levels 
of anxiety than those who had been diagnosed over two appointments, but this difference was not 
statistically significant.15 A significant difference was found eight weeks later, when women diagnosed 
with cancer in the one-stop clinic reported higher levels of depression than those diagnosed in a two-
stop clinic.  
Three papers assessed GPs views on the acceptability of one-stop clinics. In one study GPs rated the 
one-stop urology clinic as a 9/10 in terms of the quality of service and information provided, and the 
resolution of their patients’ presenting symptoms, and 7/10 in terms of accessibility.33  In another 
study, 88% of GPs said they were satisfied and would use the one-stop lymph node clinic again.41 In 
the third study, 91% of GPs rated the clinic as “good” or “very good”, and 84% said they preferred the 
one-stop clinic for the management of patients with dyspepsia while only 11% said they preferred 
direct access endoscopy.40 
Finally, one study reported that when patients were reassured by all tests being negative in the usual 
care multi-stop clinic, they were significantly more likely to have further clinic attendance than those 
reassured in the one-stop clinic (54.4% versus 44.4%, p=0.0005).15 
 
Discussion 
In this systematic review and meta-analysis we aimed to summarise the current evidence for one-stop 
clinics for the investigation of patients from primary care with symptoms that could be indicative of 
cancer. The cancer CR ranged from 1.7-42.8% and the non-cancer CR ranged from 30.3-82.1%, 
depending on indication(s) for referral. The studies comparing one-stop and multi-stop pathways 
reported similar CRs with significantly shorter intervals from referral to testing associated with one-
stop clinics. Significantly more patients received a diagnosis on the same day and significantly fewer 
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patients required additional clinic appointments after attending a one-stop clinic. Patient and GP 
satisfaction was found to be generally high, and the reported adverse effects of one-stop clinics were 
either statistically non-significant or of little clinical significance.42 
Strengths and weaknesses 
To our knowledge this is the first systematic review to summarise the evidence for one-stop clinics. 
We performed a comprehensive search and applied strict selection criteria to ensure that we only 
included studies examining the outcomes of one-stop clinics in patients referred from primary care. 
The majority of studies were, however, judged to be of poor quality: most were descriptive 
retrospective audits limiting external validity, and very few studies included a comparator group. As a 
result, we felt that making firm conclusions about the diagnostic performance of one-stop pathways in 
relation to multi-stop pathways would be inappropriate. Furthermore, all of the included one-stop 
clinics focused on individual symptoms or specialties, e.g. lower GI symptoms or urology clinic, but all 
patients attending these clinics may not have had the same symptoms. For example, some clinics 
which investigated abnormal vaginal bleeding included women with post-menopausal bleeding only, 
while others included a range of symptoms from irregular menstruation to post-coital bleeding: 
symptoms which carry different positive predictive values for cancer and indicate heterogeneity within 
the study populations.  
Comparison with the literature 
Although high quality studies examining one-stop clinics are rare, this is just one of a number of 
diagnostic testing pathways that are being explored. As well as one-stop clinics, direct access testing 
is being studied as a route where GPs may refer a patient for a specific diagnostic test, for example 
CT scan or MRI, without the need to refer to or consult with a specialist with the aim of speeding up 
access to testing.43 A recent systematic review reported that like one-stop clinics, direct access clinics 
were associated with a reduction in time from referral to testing.8 Unlike one-stop clinics, however, 
there was no significant reduction in time from referral to diagnosis. This review also found that the 
cancer and non-cancer CRs for direct access clinics were similar to those of usual care clinics, and 
GPs and patients rated their performance highly.  
Another route to testing where there is a small but growing body of literature is multi-disciplinary 
centres (MDCs). MDCs are similar to one-stop clinics in that the patient is provided with all the 
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necessary tests and consultations for a diagnosis at the same centre. Unlike one-stop clinics, 
however, MDCs tend not to be focussed on specific specialties instead investigating a range of, often 
non-specific, symptoms. MDCs may also require the GP to have ordered certain tests, for example 
blood tests or even some diagnostic imaging, before referral to the MDC is accepted. Despite these 
differences, the aim of both one-stop clinics and MDCs to provide a comprehensive range of tests in 
one centre warrants comparisons between their outcomes. The Danish non-specific symptoms and 
signs of cancer patient pathway (NSSC-CPP) and the pathways under investigation by Cancer 
Research UK’s Accelerate Coordinate and Evaluate (ACE) program are examples of MDCs at 
different stages of implementation and assessment.44,45 The NSSC-CPP has reported a cancer CR of 
16% in 1278 patients referred to the pathway which is within the range of cancer CRs reported by 
one-stop clinic studies included in this review even without the preliminary GP ordered tests.46 
Furthermore, the introduction of cancer pathways such as the NSSC-CPP have resulted in a 
significant reduction in waiting times for patients across a range of cancer types.47 We too found that 
one-stop clinics could significantly reduce the time from GP referral to clinic appointment, with an 
average waiting time of 15 days, just outside the 14 day target set by the Independent Cancer 
Taskforce.1  
Implications for research and practice 
The decrease in time from GP referral to testing, and the comparable cancer CRs between one-stop 
and multi-stop clinics, provide some evidence in support of the use of one-stop clinics. This evidence, 
however, needs to be strengthened so that appropriate comparisons and evidence-based conclusions 
can be reached about the relative effectiveness of one-stop and multi-stop clinics. Approaches which 
remove the need for patients to attend multiple appointments in order to receive a diagnosis have 
recently been championed in recommendations for cancer research.1 One-stop clinics investigating 
specific, often ‘red flag’ symptoms and MDCs investigating non-specific symptoms both fulfil these 
recommendations.44,48 Despite the savings that may occur from a reduced number of consultations, 
there have been reports that the staff requirements of one-stop clinics can result in higher costs.14 
Currently, due to the paucity of studies that compare the costs and outcomes of one-stop clinics to a 
multi-stop diagnostic process, it is not possible to determine whether these costs outweigh the 
benefits.  
11 
 
In addition, although we have shown that one-stop clinics are associated with reduced time from GP 
referral to testing and diagnosis, it is still unknown whether one-stop clinics are associated with earlier 
cancer stage at diagnosis or increased survival. None of the studies included in this review discussed 
the clinics’ impact on the stage at which cancer diagnoses were made. NHS England has recently 
allocated £200 million to achieving faster and earlier cancer diagnosis49 as part of its strategy to meet 
the Independent Cancer Taskforce’s goal of 57% of cancer patients surviving 10 years and 75% 
surviving one year by 2020.1 One-stop clinics could be a valuable tool in achieving this goal, but with 
the lack of studies examining stage of diagnosis we only have part of the evidence needed to 
determine whether they could have a role to play.  
The gaps in the evidence should be addressed by studies heeding the shortcomings of previous 
research in this field. The studies that we assessed to be of higher quality were those that described a 
randomised trial rather than observational design,14 provided a full account of the patients that 
entered the study,14,17,23,30,36 and justified the statistical methods used.37 These are only a small 
proportion of the studies included in this review and this highlights the need for more, high quality 
studies that make use of prospective designs, randomisation of patients to one-stop and comparator 
groups, and rely less on clinical records data not collected for the purposes of the study.  
The overwhelming majority of studies concluded that one-stop clinics were a patient-centred, efficient 
route to diagnosis. There was less agreement about how one-stop clinics should be delivered. Some 
authors suggested cost savings could be made by using existing resources rather than investing in 
new facilities.37 Contrary to this, others stated that the difficulties which arose from patients having to 
navigate the hospital to attend different investigations meant that restructuring was necessary so that 
investigation, consultation, and administration could be carried out side by side.38 While a third group 
of authors felt that diagnostic tests should be performed away from the consultation to prevent the test 
being seen as inevitable and to emphasise the importance of the consultation.40 Initial difficulties 
running one-stop clinics settled over time and clinicians were able to see as many patients as they 
had previously in the multi-stop clinic.15 As one-stop clinics produced similar diagnosis rates to multi-
stop clinics or screening programmes, without increasing demands on resources or increasing 
diagnostic errors15,29, it seems unlikely that one-stop clinics will place extra demands on the clinical 
teams who will treat the detected cancers but rather that they may ease demand if it can be shown 
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that cancers are detected at an earlier, more treatable stage. This is a hypothesis that should be 
addressed in future research.  
If one stop clinics encourage referral of patients who would not have been referred to standard multi-
step pathways, then there is a potential risk of overdiagnosis of cancer – diagnosis of a cancer that 
would not have caused harm during a patient’s lifetime. Overdiagnosis of cancer is most commonly 
described in the context of screening but it is possible to diagnose cancer in patients with symptoms 
from another cause, especially when lower risk patients are tested.50  Based on the findings of this 
review we are unable to comment on the risk of overdiagnosis in one-stop clinics: only one study 
reported patients diagnosed with asymptomatic breast cancer and most also had symptomatic breast 
cancer.29  Some authors considered the CR’s for cancer and serious disease to be too low30,39 whilst 
others concluded that testing more patients to reduce the risk of under-diagnosis was important.19,37 
GPs will play a vital role in minimising inappropriate referrals to achieve a balance between under- 
and overdiagnosis. 
Conclusion 
In conclusion, this study provides a first review of the literature on one-stop clinics to investigate 
symptoms that could be indicative of cancer. Streamlining services in the NHS, which is beset with 
financial difficulties and ever-growing demands on resources, is an intuitive strategy to begin tackling 
these issues. This is especially pertinent for conditions such as cancer with patients benefitting from 
expedited diagnosis. The shortened time from referral to test and higher numbers of patients receiving 
their diagnosis on the same day are efficiency savings that we have shown to be possible with one-
stop clinics and these provide evidence in support of their continued use and increased rigorous 
assessment.  
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Table 1. Characteristics of the papers included in systematic review of GP referrals to one-stop clinics (1998 – 2016): First author and reference, country, study design, 
participant selection, indication(s) for referral, total patients, number of patients in one-stop group, number of patients in comparator group.   
(GI: gastrointestinal; PSA: prostate specific antigen) 
First author and 
reference 
Country study 
conducted Study design Participant selection 
Indication(s) for one-stop 
clinic referral 
Number 
patients 
included 
(Total N) 
One-stop 
group (n) 
Comparator 
group (n) 
Abu (2001) 26 UK Cohort Consecutive Abnormal vaginal bleeding 239 113 126 
Agaba (2006) 31 UK Cross-sectional Consecutive Lower GI symptoms 250 250 - 
Al Hamarneh (2013) 
6 UK Cohort 
Consecutive Neck lump 333 333 - 
Barrass (2013) 37 UK Cross-sectional Consecutive Urological 200 100 100 
Britton (2009) 27 UK Cross-sectional Consecutive Breast symptoms 7613 7613 - 
Coull (2009) 38 UK Cross-sectional Consecutive Urological 257 257 - 
Dey (2002) 14 UK Randomised controlled trial All patients in the time period Breast symptoms 478 267 211 
Eltahir (1999) 28 UK Cohort Consecutive Breast symptoms 1110 1110 - 
Forde (2011) 18 Ireland Cohort Consecutive Elevated PSA 215 215 - 
Gregory (2000) 41 UK Cross-sectional Consecutive Enlarged lymph node 82 82 - 
Harcourt (1998) 15 UK Randomised controlled trial Consecutive Breast symptoms 791 416 375 
Jones (2001) 20 UK Cross-sectional Consecutive Abnormal vaginal bleeding 93 93 - 
Lee (2007) 16 Australia Cross-sectional Consecutive Lower GI symptoms 1529 1529 - 
Lotfallah (2005) 21 UK Cross-sectional Consecutive Abnormal vaginal bleeding 308 308 - 
McCombie (2015) 17 Australia Cohort Consecutive Elevated PSA 200 200 - 
Mehrotra (2011) 29 UK Cross-sectional All patients with breast cancer Breast symptoms 4400 4400 - 
Melleney (2002) 39 UK Cross-sectional Consecutive Dyspepsia  100 100 - 
Mohamed (2003) 22 UK Cross-sectional Consecutive Abnormal vaginal bleeding 80 80 - 
Moore (2009) 34 UK Cross-sectional Consecutive Testicular symptoms 845 845 - 
Muthuveloe (2016) 35 UK Cross-sectional Consecutive Testicular symptoms 1757 1757 - 
Panda (2002) 23 UK Cohort Consecutive Abnormal vaginal bleeding 522 522 - 
Patel (2000) 30 UK Cohort Consecutive Breast symptoms 321 321 - 
Rochester (2008) 36 UK Cohort Consecutive Testicular symptoms 1017 1017 - 
Rutter (1998) 40 UK Cross-sectional Consecutive Dyspepsia 362 362 - 
Shah (2016) 33 UK Cohort Consecutive Elevated PSA 729 729 - 
Sulaiman (2004) 24 UK Cohort Consecutive Abnormal vaginal bleeding 146 95 51 
Tan (1998) 19 Singapore Cross-sectional Consecutive Haematuria 113 113 - 
Toomey (1998) 32 UK Cohort Consecutive Lower GI symptoms 344 344 - 
Yakasai (2011) 25 UK Cross-sectional Consecutive Abnormal vaginal bleeding 753 753 - 
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Table 2. Cancer and non-cancer conversion rates by indication for referral in adult patients referred to a 
one-stop clinic with symptoms that could be indicative of cancer 
Indication for 
One-Stop referral Conversion Rates 
Studies 
(N) 
Cancer Studies 
(N) 
Non-cancer diagnoses 
Range (%) Pooled % (95% CI) Range % 
Pooled % (95% 
CI) 
Abnormal 
vaginal 
bleeding 
One-
stop  
6 1.3 – 5.2 3.7 (2.7 – 4.9) 
5 
4.2 – 58.1 30.3 (17.0 – 45.5) 
Multi-
stop  
1 5.9 - 
1 
17.7 - 
Breast 
symptoms 
One-
stop  
6 5.3 – 16.1 8.5 (6.8 – 10.4) 
2 
68.9 – 90.0 81.5 (78.3 – 84.6) 
Multi-
stop  
2 9.1 – 12.3 10.2 (7.8 – 12.8)* 
1 
64.5 - 
Lower 
gastrointestinal 
symptoms 
3 0.9 – 3.2 1.7 (0.5-3.5) 
3 
59.2 – 96.8 82.1 (61.8 – 95.8) 
Elevated PSA 3 31.1 – 55.5 42.8 (28.5-57.7) 1 24 - 
Haematuria 1 14.2 - 1 28.3 - 
Enlarged lymph 
node 
1 19.5 - 
1 
80.5 - 
Neck lump 1 16.2 - 1 64.3 - 
Testicular 
symptoms 
3 1.0 – 5.6 3.2 (0.9 – 6.7) 
3 
15.0 – 75.7 49.5 (14.0 – 85.4) 
Upper 
gastrointestinal 
symptoms 
2 3.3 – 7 3.9 (2.3 – 5.9) 
2 
41.2 – 72.0 48.2 (43.6-52.7) 
*p=0.28 
 
